SATELLOS Retains BND Projects Inc. for Strategic Investor Relations Services
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO,
SATELLOS Announces Appointment of J. Robert Hall as Vice-President, Finance and Administration
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES Toronto,
SATELLOS Announces Evidence for Regeneration in Severe Model of Duchenne
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO,
SATELLOS Announces Second Quarter 2021 Financial Results and MD&A
Toronto, Ontario -- (August 30, 2021) Satellos Therapeutics Inc. (TSXV: MSCL) ("Satellos"), formerly iCo Therapeutics
SATELLOS Announces High Resolution Crystal Structure of Duchenne Drug Target
SATELLOS BIOSCIENCE Announces High Resolution Crystal Structure of Duchenne Drug Target TORONTO, ONTARIO –August 26,
SATELLOS Announces Partnership with Jesse’s Journey
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO,
SATELLOS Announces Joint Development Agreement with NW PharmaTech Limited for Oral CBD
TORONTO, ONTARIO –August 18, 2021, Satellos Bioscience Inc. (“Satellos”) (TSX-V:MSCL), formerly iCo Therapeutics, Inc., and
SATELLOS and iCo Announce Completion of Reverse Takeover
Satellos and iCo Announce Completion of Reverse Takeover Toronto, Ontario--(Newsfile Corp. - August 13, 2021)
iCo Therapeutics Inc. Announces Shareholder Approval of business combination with Satellos Bioscience Inc.
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES. iCo
iCo Therapeutics Inc. Announces TSX Venture Exchange Conditional Approval and Provides Update regarding Business Combination with Satellos Bioscience Inc.
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES. iCo